Abstract: An approach is provided for dynamically controlling power distribution amongst a plurality of charging station ports based on one or more objectives. A method includes obtaining input data, wherein the input data includes at least one of: user data associated with one or more current charging station users, or non-user data that is not associated with the current charging station users. The method includes processing the input data through one or more machine learning engines, wherein the one or more machine learning engines are trained to determine a particular power distribution, among the plurality of charging station ports, that achieves one or more objectives. The method includes configuring the plurality of charging station ports according to the particular power distribution. The particular power distribution specifies a maximum charging rate or a percentage of a power budget for each of the plurality of charging station ports.

Abstract: An approach is provided for dynamically controlling power distribution amongst a plurality of charging station ports based on one or more objectives. A method includes obtaining input data, wherein the input data includes at least one of: user data associated with one or more current charging station users, or non-user data that is not associated with the current charging station users. The method includes processing the input data through one or more machine learning engines, wherein the one or more machine learning engines are trained to determine a particular power distribution, among the plurality of charging station ports, that achieves one or more objectives. The method includes configuring the plurality of charging station ports according to the particular power distribution. The particular power distribution specifies a maximum charging rate or a percentage of a power budget for each of the plurality of charging station ports.

Abstract: Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer.

Abstract: Disclosed are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein W, Y, Z, R1, R2, R3, R4 and R5 are described herein, and methods of using said compounds in the treatment of cancer.

Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.

Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.

Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Abstract: A novelty game that utilizes a plurality of alphanumeric-shaped playing pieces. Each playing piece has a body shaped as a letter or number. The body has a flat face surface, a parallel rear surface, and side edges that interconnect the face surface to the rear surface. The width of the side edges is large enough to enable each playing piece to stand upright on-edge and unsupported. A plurality of mechanical connectors are present on the playing pieces. The connectors enable each playing piece to physically interconnect with at least two others of the playing pieces to form an assemblage of letters or numbers word. When a conjoined assemblage is formed, only one or some of the playing pieces touch the ground. Most are supported in the air as the playing pieces build atop one another.

Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

Abstract: A game assembly and its method of play. The game assembly has a game board. A three-dimensional underlay is positioned under the game board. Openings are formed through the game board that enable a person to see into the underlay. The underlay is comprised of a basin that is partially occupied with fill material. Search objects are mixed with the fill material. Sometimes the search objects are covered by the fill material, at other times they are not. Cover structures are provided. The cover structures selectively cover the openings in the game board. To play the game, a player selects a search object. A player also selects a cover structure. The cover structure selected by the player is removed and the player looks through the exposed opening for the selected search object. The game is won when a predetermined number of search objects are found by a single player.

Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, having antimicrobial activity, processes for their preparation, compositions containing them and to their use in medicine.

Abstract: A method of inhibiting MetRS activity comprises administering to a patient in need thereof a MetRS inhibiting effective amount of a compound of the formula (I). A method of treating a resistant or multiply-resistant E. faecalis infection, a resistant or multiply-resistant S. aureus infection, and/or a resistant or multiply-resistant S. epidermidis infection comprises administering to a patient in need thereof an antibacterially effective amount of a compound of the formula (I).

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.